- NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." style="word-wrap: break-word; margin: 0px; padding: 0px; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; font-size: inherit; line-height: inherit; font-family: inherit; vertical-align: baseline; color: rgb(29, 134, 187); text-decoration: underline">NDC Code(s): 57664-273-08, 57664-273-13, 57664-273-18, 57664-274-08, view less
57664-274-13, 57664-274-18, 57664-275-08, 57664-275-13, 57664-275-18
- Packager: Caraco Pharmaceutical Laboratories, Ltd.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: CIV
- Marketing Status: Abbreviated New Drug Application
DRUG LABEL INFORMATION
Updated December 4, 2013
If you are a consumer or patient please visit this version.
Clonazepam USP is a benzodiazepine and is chemically designated as 5-(2-chlorophenyl)- 1,3-dihydro-7-nitro- 2H -1,4-benzodiazepine-2-one. It is a light yellow crystalline powder. It has a molecular weight of 315.72 and the following structural formula.
Each tablet for oral administration, contains 0.5 mg, 1 mg, or 2 mg of clonazepam. In addition each tablet contains the following inactive ingredients: Lactose Monohydrate, Microcrystalline Cellulose, Pregelatinized Starch, Magnesium Stearate, D&C Yellow No. 10 Aluminum Lake (0.5 mg only), FD&C Blue No.1 Aluminum Lake (1 mg only).CLOSE
- CLINICAL PHARMACOLOGY
The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Convulsions produced in rodents by pentylenetetrazol or, to a lesser extent, electrical stimulation are antagonized, as are convulsions produced by photic stimulation in susceptible baboons. A taming effect in aggressive primates, muscle weakness and hypnosis are also produced. In humans, clonazepam is capable of suppressing the spike and wave discharge in absence seizures (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizures.